Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$435M |
| 2 |
Amazon
AMZN
|
+$334M |
| 3 |
Moderna
MRNA
|
+$53.9M |
| 4 |
Linde
LIN
|
+$44.2M |
| 5 |
DTE Energy
DTE
|
+$43.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$63.6M |
| 2 |
Comcast
CMCSA
|
+$39.7M |
| 3 |
Evergy
EVRG
|
+$38.5M |
| 4 |
Public Service Enterprise Group
PEG
|
+$38.4M |
| 5 |
Bio-Techne
TECH
|
+$30.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.37% |
| 2 | Consumer Discretionary | 10.36% |
| 3 | Financials | 7.14% |
| 4 | Industrials | 6.8% |
| 5 | Healthcare | 6.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DMC
1751
Del Monte Corp
DMC
$1.5B
| $296K | ﹤0.01% |
+9,003
| New | +$290K |
|
1752
MillerKnoll
MLKN
$1.58B
| $296K | ﹤0.01% |
+6,275
| New | +$284K |
|
|
DCRN
1753
DELISTED
Decarbonization Plus Acquisition Corporation II Class A Common stock
DCRN
| $296K | ﹤0.01% |
+30,000
| New | +$294K |
|
1754
BARK
BARK
$93.4M
| $295K | ﹤0.01% |
+1,332
| New | +$288K |
|
1755
Moog Inc Class A
MOG.A
$11.9B
| $295K | ﹤0.01% |
3,506
-3,620
| -51% | -$313K |
|
1756
AZZ Inc
AZZ
$4.16B
| $293K | ﹤0.01% |
5,666
-11,280
| -67% | -$593K |
|
1757
Rhythm Pharmaceuticals
RYTM
$7.8B
| $293K | ﹤0.01% |
+14,944
| New | +$310K |
|
|
LHCG
1758
DELISTED
LHC Group LLC
LHCG
| $292K | ﹤0.01% |
1,459
-970
| -40% | -$195K |
|
|
BPYU
1759
DELISTED
Brookfield Property REIT Inc. Class A Common Stock
BPYU
| $292K | ﹤0.01% |
15,438
-15,016
| -49% | -$275K |
|
1760
Cabaletta Bio
CABA
$546M
| $291K | ﹤0.01% |
+33,857
| New | +$333K |
|
1761
Noodles & Co
NDLS
$92.5M
| $291K | ﹤0.01% |
2,915
-225
| -7% | -$20.9K |
|
1762
Flywire
FLYW
$2.34B
| $290K | ﹤0.01% |
+7,900
| New | +$265K |
|
|
TBHC
1763
DELISTED
The Brand House Collective
TBHC
| $290K | ﹤0.01% |
12,688
-15,333
| -55% | -$412K |
|
1764
Rayonier Advanced Materials
RYAM
$582M
| $290K | ﹤0.01% |
43,396
+21,462
| +98% | +$175K |
|
1765
Team
TISI
$110M
| $290K | ﹤0.01% |
+4,328
| New | +$394K |
|
1766
Assembly Biosciences
ASMB
$719M
| $289K | ﹤0.01% |
6,203
+4,957
| +398% | +$246K |
|
1767
Global Industrial
GIC
$1.51B
| $287K | ﹤0.01% |
7,814
+885
| +13% | +$33.7K |
|
1768
Heritage Insurance Holdings
HRTG
$1.02B
| $287K | ﹤0.01% |
+33,417
| New | +$308K |
|
|
MRSN
1769
DELISTED
Mersana Therapeutics
MRSN
| $287K | ﹤0.01% |
+846
| New | +$320K |
|
1770
QuinStreet
QNST
$1.15B
| $287K | ﹤0.01% |
15,469
-7,561
| -33% | -$143K |
|
1771
State Street SPDR S&P 600 Small Cap Value ETF
SLYV
$5.04B
| $287K | ﹤0.01% |
+3,353
| New | +$285K |
|
1772
Harmonic Inc
HLIT
$1.34B
| $286K | ﹤0.01% |
33,525
+21,378
| +176% | +$164K |
|
|
AIOT
1773
PowerFleet Inc
AIOT
$395M
| $285K | ﹤0.01% |
+39,624
| New | +$289K |
|
|
EXPR
1774
DELISTED
Express, Inc.
EXPR
| $284K | ﹤0.01% |
+2,190
| New | +$185K |
|
|
HNGR
1775
DELISTED
Hanger Inc.
HNGR
| $283K | ﹤0.01% |
11,211
+442
| +4% | +$11K |
|
Similar funds
Michael Gelband's Q2 2021 Portfolio in Review
As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Michael Gelband deployed $1.88B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.
- Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
- Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
- Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
- Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
- Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
- Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
- Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.